Levodopa/Benserazid Ratiopharm

Levodopa, the active ingredient in Levodopa/Benserazid Ratiopharm, is an Antiparkinson agent presented as an oral tablet for oral use. It is used to treat Parkinson's disease by replenishing central dopamine levels in patients with motor symptoms. GNH USA supplies Levodopa/Benserazid Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levodopa/Benserazide is an antiparkinson medication that targets dopaminergic pathways to improve motor function in Parkinsonian disorders. - Parkinson's disease: reduces rigidity, tremor, and bradykinesia, improving overall motor control. - Parkinsonian syndrome: alleviates motor deficits associated with secondary Parkinsonism. - Early-stage Parkinson's disease: helps maintain functional independence by enhancing dopamine availability.

Levodopa/Benserazide may cause a range of adverse reactions. Patients should be monitored for both common and serious events.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Orthostatic hypotension: dizziness upon standing. - Dyskinesia: involuntary movements, especially with higher doses. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening hyperthermia and rigidity. - Severe psychiatric disturbances: hallucinations or psychosis. - Cardiac arrhythmias: irregular heart rhythm requiring urgent care.

Levodopa/Benserazide requires careful patient assessment and monitoring. - Dose titration: start low and increase gradually to minimize dyskinesia. - Cardiovascular monitoring: watch for orthostatic hypotension and arrhythmias. - Psychiatric evaluation: monitor for hallucinations or mood changes. - Drug interactions: avoid concurrent MAO‑B inhibitors without washout period. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Levodopa/Benserazide can interact with several medications, affecting its efficacy or safety.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Antipsychotics (e.g., haloperidol): may diminish antiparkinson effect.

Moderate Interactions (Monitor Closely): - Iron supplements: reduce levodopa absorption; separate dosing by at least 2 hours. - Antihypertensives: may exacerbate orthostatic hypotension. - Serotonergic agents: increase risk of serotonin syndrome when combined with MAO‑B inhibitors.